{
  "guideline": {
    "id": "PA166104934",
    "name": "Annotation of DPWG Guideline for azathioprine and TPMT",
    "source": "DPWG",
    "version": 33,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104934",
    "relatedChemicals": [
      {
        "id": "PA448515",
        "name": "azathioprine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA356",
        "name": "thiopurine S-methyltransferase",
        "symbol": "TPMT"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299167",
      "name": "Recommendation PA166299167",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA448515",
          "name": "azathioprine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061530,
        "html": "<p>The guideline does not provide a recommendation for azathioprine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on azathioprine."
      ],
      "lookupKey": {
        "TPMT": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299166",
      "name": "Recommendation PA166299166",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448515",
          "name": "azathioprine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061529,
        "html": "<p>Choose an alternative or start with 10% of the standard dose.\nAny adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness.\nIf the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur.</p>\n"
      },
      "implications": [
        "Grade ≥ 2 leukopaenia and intolerance occurred in 98% of these patients with standard therapy. The gene variation increases the quantities of the active metabolites of azathioprine and mercaptopurine."
      ],
      "lookupKey": {
        "TPMT": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166299165",
      "name": "Recommendation PA166299165",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448515",
          "name": "azathioprine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061528,
        "html": "<p>IMMUNOSUPPRESSION\nStart with 50% of the standard dose\nAdjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness.\nDose adjustment is not required for doses lower than 1.5 mg/kg per day for azathioprine or 0.75 mg/kg per day for mercaptopurine.\nNote: more stringent dose reductions are necessary if the patient is also NUDT15 IM or NUDT15 PM.</p>\n"
      },
      "implications": [
        "Grade ≥ 2 leukopaenia occurs in 23% of these patients with normal therapy for immunosuppression. The genetic variation increases the quantity of the active metabolites of azathioprine and mercaptopurine."
      ],
      "lookupKey": {
        "TPMT": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ],
  "version": "2023-12-19-10-38"
}